2024 — Using artificial intelligence technology to identify patterns of DNA fragments associated with lung cancer, researchers have developed and validated a liquid biopsy that may help identify ...

Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its generative AI model in Nature Communications. The paper ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements ...

In recent research published in eGastroenterology, Dr. J-Matthias Löhr and colleagues provide an in-depth review of ...

"Our mission is to make cancer less deadly through widely accessible next-generation early detection blood tests." Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode ...

A breakthrough AI-powered liquid biopsy combining cell-free DNA and protein biomarkers improves early detection of ovarian ...

Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Lung Reagents (research use only) for liquid biopsy samples. Aspyre Lung identifies established non-small ...

FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...

This helps provide better diagnosis, with at least 100 times more information than the current liquid biopsy testing ... The ...